

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NATL BREAST CANCER COALITION

2. Address:

1707 L ST NW #1060, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

4. Contact Name: JENNIFER KATZ

Telephone: 202-973-0595

E-mail (optional): jkatz@natlbcc.org

Senate ID #: 52652-12

House ID #: 34898000

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2000 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 100,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Department of Defense Breast Cancer Research Program Dear Colleague letter to the Chairman of the Appropriations Defense Subcommittee in support of level funding of \$175 million for the Department of Defense Breast Cancer Research Program. The Breast and Cervical Cancer Treatment Act H.R. 1070, Breast and Cervical Cancer Treatment Act of 1999, Section 1, "Optional Medicaid coverage of certain breast or cervical cancer patients." S. 662, Breast and Cervical Cancer Treatment Act of 1999, Section 1, "Optional Medicaid coverage of certain breast or cervical cancer patients." Breast Cancer and Environmental Research Act of 1999 H.R. 3433 / S. 2287, Breast Cancer and Environmental Research Act of 1999, Section 3, Amendments to Subpart 12 of part C of title IV of the Public Health Service Act that add research centers regarding environmental factors related to breast cancer. Medicare Cancer Clinical Trial Coverage Act of 1999 H.R. 1388, Medicare Cancer Clinical Trial Coverage Act of 1999, all provisions related to establishing "a demonstration project to study and provide coverage of routine patient care costs for Medicare beneficiaries with cancer who are enrolled in an approved clinical trial program" S. 784, Medicare Cancer Clinical Trial Coverage Act of 1999, all provisions related to establishing a demonstration project to study and provide coverage of routine patient care costs for Medicare beneficiaries with cancer who are enrolled in an approved clinical trial program Genetic Nondiscrimination Legislation H.R. 306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Section 2, Amendments to Employee Retirement Income Security Act of 1974; Subsection 714 Prohibition of health insurance discrimination on the basis of genetic information and Section 3 Amendments to the Public Health Service Act, Subsection 9814, Prohibition of discrimination by group health plans on the basis of genetic information. H.R. 2457 / S. 1322, Genetic Nondiscrimination in Health Insurance and Employment Act of 1999, Title I, all provisions relating to the prohibition of health insurance discrimination on the basis of predictive genetic information; Title II, all provisions relating to the prohibition of employment discrimination on the basis of predictive genetic information. Patients' Bill of Rights: H.R. 2723, The Bipartisan Consensus Managed Care Act of 1999, Title I, Subtitle A I Grievance and Appeals, improving managed care through internal and external appeals processes; Subtitle B I Access to Care, Sec. 114 I providing for access to specialty care, Sec. 117 I providing for continuity of care, and Sec. 119 I providing for individuals participating in approved clinical trials. S. 6, Patients' Bill of Rights Act of 1999, Subtitle A, all provisions relating to access to care specifically, Section 106, coverage for individuals participating in approved clinical trials and Section 105, continuity of care provisions. Also Subtitle F, Section 152, "standards relating to benefits for certain breast cancer treatment" and Subtitle D, grievance and appeals procedures.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

President of the U.S.

SENATE

Vice President of the U.S.

18. Name of each individual who acted as a lobbyist in this issue area:

Name: KATZ, JENNIFER

Covered Official Position (if applicable): N/A

Name: LECLAIR, DANIELLE

Covered Official Position (if applicable): N/A

Name: VISCO, FRANCES M.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 14, 2001

Printed Name and Title: ALANA WEXLER - LEGISLATIVE AND POLICY ASSOCIATE